Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)
Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.
Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.
The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Gaojun Teng, MD
- 電話番号:+86 13805171500
- メール:gjteng@seu.edu.cn
研究連絡先のバックアップ
- 名前:Binyan Zhong, MD
- 電話番号:+86 15850522044
- メール:byzhongir@sina.com
研究場所
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- The First Affiliated Hospital, Sun Yat-sen University
-
コンタクト:
- Ming Kuang
- 電話番号:020-87755766
- メール:kuangm@mail.sysu.edu.cn
-
コンタクト:
- Zhenwei Peng
- メール:pzhenw@mail.sysu.edu.cn
-
副調査官:
- Wenzhe Fan
-
Guangzhou、Guangdong、中国、510317
- Guangdong Second People's Hospital
-
コンタクト:
- Chengjiang Xiao
- 電話番号:+86 13602808387
- メール:Xxx196610@163.com
-
Guangzhou、Guangdong、中国、510168
- Jinshazhou Hospital of Guangzhou University of Chinese Medicine
-
コンタクト:
- Liangliang Qiao
- 電話番号:+86 13544539881
- メール:271937316@qq.com
-
Guangzhou、Guangdong、中国、511400
- The Affiliated Panyu Central Hospital of Guangzhou Medical University
-
コンタクト:
- Fuxi Huang
- 電話番号:+86 18902299938
- メール:Fuxihuang2006@126.com
-
Guangzhou、Guangdong、中国、524003
- The Second Affiliated Hospital of Guangdong Medical University
-
コンタクト:
- Kangshun Zhu
- 電話番号:+86 13602864242
- メール:Zhksh010@163.com
-
Jiangmen、Guangdong、中国、529030
- Jiangmen Central Hospital
-
コンタクト:
- Yuchuang Liang
- 電話番号:+86 13322888181
- メール:jmlyc@21cn.com
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Wuhan Union Hospital of China
-
コンタクト:
- Xuefeng Kan
- 電話番号:+86 13545874189
- メール:xkliulang1314@163.com
-
-
Hunan
-
Changsha、Hunan、中国、410013
- The Third XIANGYA Hospital of Central South University
-
コンタクト:
- Qi Liang
- 電話番号:+86 137 8731 8180
- メール:csuliangqi10@163.com
-
Changsha、Hunan、中国、410011
- The Second Xiangya Hospital of Central South University
-
コンタクト:
- Yudong Xiao
- 電話番号:+86 136 3740 3027
- メール:xiaoyudong222@csu.edu.cn
-
-
Jiangxi
-
Ganzhou、Jiangxi、中国、341000
- Ganzhou Hospital-Nanfang Hospital, Southern Medical University
-
コンタクト:
- Yusheng Song
- 電話番号:+86 135 7675 2988
- メール:646993126@qq.com
-
Nanchang、Jiangxi、中国、330209
- The First Affiliated Hospital of Nanchang University
-
コンタクト:
- Junhua Ai
- 電話番号:+86 18170936163
- メール:aijh0001@163.com
-
-
Shandong
-
Qingdao、Shandong、中国、266000
- The Affiliated Hospital of Qingdao University
-
コンタクト:
- Song Wang
- 電話番号:+86 18661805592
- メール:derekqyfy@126.com
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
-
コンタクト:
- Chang Liu
- 電話番号:+86 18980606382
- メール:drliuchang@wchscu.cn
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310022
- Zhejiang Cancer Hospital
-
コンタクト:
- Gaojun Teng
- 電話番号:+86 0571 - 88122222
- メール:gjteng@seu.edu.cn
-
コンタクト:
- Binyan Zhong
- 電話番号:+86 15850522044
- メール:byzhongir@sina.com
-
副調査官:
- Jiaping Zheng
-
Jinhua、Zhejiang、中国、321000
- Jinhua Municipal Central Hospital
-
コンタクト:
- Xiaogang Hu
- 電話番号:+86 135 8866 8173
- メール:heartdoctor@163.com
-
Lishui、Zhejiang、中国、323020
- Lishui Central Hospital
-
コンタクト:
- Jiansong Ji
- 電話番号:+86 0578-2285888
- メール:jjstcty@sina.com
-
コンタクト:
- Jianfei Tu
- メール:jianfei1133@163.com
-
Ningbo、Zhejiang、中国、315010
- Ningbo No.2 Hospital
-
コンタクト:
- Yunjie Chen
- 電話番号:+86 13857877137
- メール:a88960317@163.com
-
Ningbo、Zhejiang、中国、315048
- Ningbo Medical Center Lihuili Hospital
-
コンタクト:
- Shengdong Wu
- 電話番号:+86 13567886669
- メール:13567886669@139.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
- No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
- At least one measurable intrahepatic lesion according to RECIST v1.1.
- ECOG performance status of 0 or 1.
- Child-Pugh class A liver function.
- Life expectancy ≥3 months.
Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:
- Absolute neutrophil count ≥1.5 × 10⁹/L;
- Platelet count ≥75 × 10⁹/L;
- Hemoglobin ≥90 g/L;
- Serum albumin ≥30 g/L;
- Total bilirubin ≤1.5 × upper limit of normal;
- AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
- TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
- Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.
Exclusion Criteria:
- Diffuse infiltrative liver lesions.
- Contraindications to TACE.
- Allergy to intravenous contrast agent.
- pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
- Patients with HIV or syphilis infection.
- Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
- History of allogeneic organ transplantation.
- Severe dysfunction of the heart, kidney, or other organs.
- Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
- Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg.
TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment.
Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed.
TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
|
|
アクティブコンパレータ:Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles.
After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival
時間枠:From randomization to death from any cause, assessed up to approximately 48 months
|
Overall survival is defined as the time from enrollment/randomization to death from any cause.
Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
|
From randomization to death from any cause, assessed up to approximately 48 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival
時間枠:From randomization to disease progression or death, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression or death from any cause.
Participants without progression or death will be censored at the last date known to be progression-free.
|
From randomization to disease progression or death, assessed up to approximately 48 months
|
|
Time to Progression
時間枠:From randomization to disease progression, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression.
Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
|
From randomization to disease progression, assessed up to approximately 48 months
|
|
Objective Response Rate
時間枠:Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Disease Control Rate
時間枠:Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Incidence of Grade ≥3 Adverse Events
時間枠:From first dose of study treatment through 28 days after the last dose of study treatment
|
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
|
From first dose of study treatment through 28 days after the last dose of study treatment
|
|
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
時間枠:Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer.
Scores are linearly transformed to a 0 to 100 scale.
For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning.
For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
|
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
時間枠:Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life.
The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity.
Higher scores in each dimension indicate more severe problems or worse health status.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Gaojun Teng, MD、Zhejiang Cancer Hospital
- 主任研究者:Min Kuang, MD、First Affiliated Hospital, Sun Yat-Sen University
- 主任研究者:Jiansong Ji, MD、The Central Hospital of Lishui City
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- RAINBOW 01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。